<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SMF</journal-id>
      <journal-title-group>
        <journal-title>Schweizerisches Medizin-Forum</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1424-4020</issn>
      <issn pub-type="ppub">1424-3784</issn>
      <publisher>
        <publisher-name>EMH Schweizerischer Ärzteverlag AG</publisher-name>
        <publisher-loc>Farnsburgerstrasse 8
CH-4132 Muttenz</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">08693</article-id>
      <article-id pub-id-type="doi">10.4414/smf.2021.08693</article-id>
      <article-categories>
        <!-- rubric -->
        <subj-group subj-group-type="Article Type">
          <subject>Wie deuten Sie diesen Befund?</subject>
        </subj-group>
        <!-- topics -->
        <subj-group subj-group-type="Classification">
          <subject>Kardiologie</subject>
          <subject>Labormedizin</subject>
          <subject>Nephrologie</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Elévation asymptomatique du taux de créatine kinase</article-title>
      </title-group>
      <contrib-group>
        <contrib id="author-1" contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Veya</surname>
            <given-names>Elisa</given-names>
          </name>
          <email/>
          <aff>Centre hospitalier universitaire vaudois Departement de medecine</aff>
        </contrib>
        <contrib id="author-2" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Bardy</surname>
            <given-names>Daniel</given-names>
          </name>
          <email/>
          <aff>CHUV service de chimie clinique</aff>
        </contrib>
        <contrib id="author-3" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Boulat</surname>
            <given-names>Olivier</given-names>
          </name>
          <email/>
          <aff>CHUV service de chimie clinique</aff>
        </contrib>
        <contrib id="author-4" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Dumans-Louis</surname>
            <given-names>Céline</given-names>
          </name>
          <email>celine.dumans-louis@chuv.ch</email>
          <aff>Rue du Bugnon 46 | Lausanne | 1011 | SWITZERLAND</aff>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" date-type="pub" iso-8601-date="2021.04.27">
        <day>27</day>
        <month>04</month>
        <year>2021</year>
      </pub-date>
      <volume>21</volume>
      <issue>1718</issue>
      <fpage>297</fpage>
      <lpage>299</lpage>
      <permissions>
        <copyright-statement>Copyright: EMH Schweizerischer Ärzteverlag AG</copyright-statement>
        <copyright-year>2021</copyright-year>
        <copyright-holder>EMH Schweizerischer Ärzteverlag AG</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>"Swiss Medical Forum" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms:</license-p>
          <license-p>Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</license-p>
          <license-p>NonCommercial — You may not use the material for commercial purposes.</license-p>
          <license-p>NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.</license-p>
          <license-p>"Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement.</license-p>
          <license-p>Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="article" xml:lang="de">
        <p>La créatine kinase (CK) est une enzyme fréquemment dosée en laboratoire. Sa valeur peut être supérieure aux intervalles de référence pour plusieurs raisons qui n’impliquent pas toujours une atteinte musculaire sous-jacente. Le taux de CK varie de façon significative selon l’origine ethnique du patient, étant particulièrement plus élevé chez les hommes d’origine africaine. Devant une élévation asymptomatique des CK, il convient d’abord d’évaluer la possibilité d’une valeur normale pour l’ethnie et le sexe du patient puis de répéter l’analyse après abstention d’activité physique durant au moins 3 jours. Si l’élévation est toujours significative, une cause non neuromusculaire (endocrinienne, métabolique, médicamenteuse) doit être écartée avant d’envisager des investigations plus complexes à la recherche de causes neuromusculaires. Les statines, souvent incriminées, ne doivent pas être arrêtées devant une élévation asymptomatique et modérée des CK.</p>
      </abstract>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
